Ann Arbor, MI Clinical Trials Report — June 2026

For Ann Arbor residents considering participation in clinical research, June 2026 presents both urgent opportunities and promising new avenues to contribute to medical science. With 957 clinical trials currently recruiting across 221 research facilities in Ann Arbor, there are numerous ways to get involved.

A significant number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals. A total of 51 trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 7 of these rapidly closing studies are still actively seeking participants without specific health conditions.

Urgent Opportunities: Trials Nearing Enrollment Close

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cardiovascular conditions and other health challenges are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Aortic valve insufficiency (2 trials)
• Aortic regurgitation (2 trials)
• Aortic insufficiency (2 trials)
• Adolescent (1 trial)
• Aggression (1 trial)
• Amputation neuroma (1 trial)
• Age-related macular degeneration (1 trial)
• Analgesics, opioids (1 trial)
• Anterior cruciate ligament (1 trial)
• Anticoagulant therapy (1 trial)

New Research Horizons in Ann Arbor

This month, Ann Arbor saw the opening of 18 new clinical trials, a notable increase from the 10 trials that launched in May 2026. This surge in new studies underscores the city's dynamic research landscape.

June brings several high-profile new trials to Ann Arbor, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is initiating a notable Phase 3 study, NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This pivotal, multicenter, global, randomized, placebo-controlled, double-blind study aims for 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo for chronic weight management.
• Kallyope Inc. is sponsoring two significant Phase 3 migraine trials:
  • NCT07645924: "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter trial aims for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine.
  • NCT07674654: "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine." This long-term safety study seeks 1,000 participants to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
• AstraZeneca is leading a Phase 2b study, NCT07652658, "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF." This study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in 359 participants with Idiopathic Pulmonary Fibrosis (IPF), including those on antifibrotic therapy.
• The University of Michigan is sponsoring NCT07676188, "Leveraging Interventions for Needs and Knowledge in Diabetes (LINKD)," which seeks 694 participants. This study aims to learn whether different tools and types of support may help people manage diabetes and related challenges, particularly concerning unmet social needs and economic burden.
• Also from the University of Michigan, NCT07665983, "The Bottle Optimization Testing Tiny Little Eaters Study," aims for 440 participants. Researchers will study how babies respond to bottle nipples with different flow rates and how this affects milk intake, feeding patterns, and sleep.

Diverse New Studies and Participant Opportunities

New trials this month are exploring a range of conditions, with the most frequent being migraine (2 trials), followed by caries, dental (1 trial), chemotherapy-induced peripheral neuropathy (1 trial), childhood obesity (1 trial), chronic weight management (1 trial), developmental stuttering (1 trial), diabetes (1 trial), hematopoietic and lymphatic system neoplasm (1 trial), and idiopathic pulmonary fibrosis (IPF) (1 trial). Drug trials account for the largest share of new studies, with 6 new drug trials, followed by 6 "OTHER" type trials, 5 device trials, 4 behavioral studies, and 2 procedure trials.

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 4 of the 18 new trials launched this month are actively seeking healthy volunteers. Across Ann Arbor, a total of 87 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Participation in clinical trials is open to a diverse range of individuals. Of the 18 new trials launched this month, 16 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial includes children, 1 is female-only, and 1 is male-only. Academic institutions continue to play a vital role in Ann Arbor's research ecosystem, with the University of Michigan sponsoring 9 new studies and the University of Michigan Rogel Cancer Center sponsoring 3. Industry sponsors like Kallyope Inc. (2 trials), AstraZeneca (1 trial), and Gasherbrum Bio, Inc. (1 trial) are also driving significant research efforts.

Ann Arbor's Research Powerhouses

Ann Arbor is home to some of Michigan's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Michigan (384 trials)
• University of Michigan Rogel Cancer Center (77 trials)
• Trinity Health Saint Joseph Mercy Hospital Ann Arbor (72 trials)
• University of Michigan Comprehensive Cancer Center (34 trials)
• C S Mott Children's Hospital (32 trials)
• Research Site (27 trials)
• University of Michigan Health System (25 trials)
• VA Ann Arbor Healthcare System, Ann Arbor, MI (20 trials)
• University of Michigan Hospital (18 trials)
• C.S. Mott Children's Hospital (16 trials)
• University of Michigan Health (8 trials)
• Trinity Health IHA - Obstetrics and Gynecology West Arbor (7 trials)

These institutions offer a broad spectrum of research, from oncology at the University of Michigan Rogel Cancer Center and Comprehensive Cancer Center, to pediatric care at C S Mott Children's Hospital, and diverse medical fields across the University of Michigan's extensive health system and Trinity Health facilities.

Expanding Your Search: Nearby Michigan Cities

While Ann Arbor offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Michigan. Cities with active trials include Detroit (7 trials), Bay City (2 trials), Bingham Farms (2 trials), Southfield (2 trials), Grand Rapids (2 trials), Ypsilanti (1 trial), Livonia (1 trial), and Royal Oak (1 trial).

As we move through June, Ann Arbor's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare and improve health outcomes for many.